Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

IOVA Iovance Biotherapeutics Inc

-0.185 (-1.57%)
Last Updated: 13:53:01
Delayed by 15 minutes


Draw Mode:

Volume 1,870,273
Bid Price 11.61
Ask Price 11.62
News -
Day High 11.94


52 Week Range


Day Low 11.47
Company Name Stock Ticker Symbol Market Type
Iovance Biotherapeutics Inc IOVA NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
-0.185 -1.57% 11.615 13:53:01
Open Price Low Price High Price Close Price Prev Close
11.68 11.47 11.94 11.80
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
16,464 1,870,273 $ 11.72 $ 21,916,308 - 3.21 - 18.33
Last Trade Time Type Quantity Stock Price Currency
13:53:01 100 $ 11.615 USD

Iovance Biotherapeutics (IOVA) Options Flow Summary

Overall Flow


Net Premium


Calls / Puts


Buys / Sells




Sweeps Ratio


Iovance Biotherapeutics Inc Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
3.21B 279.31M - 1.19M -444.04M -1.59 -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- - - -

more financials information »

Iovance Biotherapeutics News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No IOVA Message Board. Create One! See More Posts on IOVA Message Board See More Message Board Posts

Historical IOVA Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week12.6413.2211.4712.194,634,039-1.03-8.11%
1 Month15.0415.9011.4713.564,747,701-3.43-22.77%
3 Months7.7518.337.3413.669,407,4193.8749.87%
6 Months3.6518.333.2110.228,409,3527.97218.22%
1 Year5.8418.333.218.757,156,7025.7898.89%
3 Years29.6033.553.2110.724,445,008-17.99-60.76%
5 Years10.7554.20813.2114.343,302,3590.8658.05%

Iovance Biotherapeutics Description

Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company. The company focused on the development and commercialization of cell therapies as novel cancer immunotherapy products designed to harness the power of a patient's immune system to eradicate cancer cells. Its lead pipeline candidate, LN-145, is an adoptive cell therapy using tumor-infiltrating lymphocytes to treat patients with refractory metastatic melanoma.

Your Recent History

Delayed Upgrade Clock